|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tauopathies such as Alzheimer's disease (AD), Pick's disease (PiD), Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) etc. represent a group of age-related neurodegenerative disorders in which tau protein loses its normal conformation mostly due to hyperphosphorylation and subsequent formation of the aggregates of defined shapes, known as Neurofibrillary Tangles (NFTs).
|
31715291 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The increase in CLU alloforms was most closely associated with increases in both insoluble Aβ42 and tau protein (p = 0.001), supporting its role in AD pathogenesis.
|
31813628 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Misfolding and aggregate formation by the tau protein has been closely related with neurotoxicity in a large group of human neurodegenerative disorders, which includes Alzheimer's disease.
|
31521630 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by fibrillar deposits of amyloid-β (Aβ) peptides and neurofibrillary tangles of Tau proteins.
|
31697060 |
2020 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease (AD) is the most common cause of dementia and is characterized by aggregation of amyloid and tau proteins in the brain.
|
31694431 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The pathophysiology involved in AD is intra-neuronal accumulation of hyper-phosphorylated tau protein as neurofibrillary tangle and extra cellular beta amyloid plaque deposition, which is due to oxidative stress.
|
31585875 |
2020 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The current review summarizes recent findings on the possible role of SELENOP in AD, with a focus on probable mechanisms: Se delivery to neurons, antioxidant activity, cytoskeleton assembly, interaction with redox-active metals (e.g., copper and iron), and misfolded proteins (amyloid beta and tau protein).
|
31250406 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
[<sup>18</sup>F]flortaucipir binds to paired helical filament tau and accurately identifies tau in Alzheimer's disease (AD).
|
31612245 |
2020 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
It reversed the increase in hippocampal amyloid beta protein, phosphorylated tau protein contents together with augmentation of neprilysin level, it also diminished levels of nuclear factor kappa-B, FAS ligand, tumor necrosis factor-alpha, malondialdehyde, and acetylcholinesterase content.These findings show the protective action of telmisartan against AD-like pathological alterations.
|
31332715 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The microtubule-associated protein Tau is strongly implicated in Alzheimer's disease (AD) and aggregates into neurofibrillary tangles in AD.
|
31698056 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
This novel tau biomarker could be used to improve diagnosis of Alzheimer's disease and to facilitate the development of drug candidates targeting tau pathology.
|
31834365 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by the presence of extracellular amyloid β plaques and intraneuronal neurofibrillary tangles of hyperphosphorylated microtubule-associated protein tau in the brain.
|
31376192 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a result, Aβ and Tau generate continually, which aggravates both autophagy dysfunction and AD.
|
31503421 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A key knowledge gap blocking development of effective therapeutics for Alzheimer's disease (AD) is the lack of understanding of how amyloid beta (Aβ) peptide and pathological forms of the tau protein cooperate in causing disease phenotypes.
|
31825838 |
2019 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer's disease (AD), where abnormal activation of this enzyme has been associated with hyperphosphorylation of tau proteins.
|
31792284 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Self-assembly of the microtubule-associated protein tau into neurotoxic oligomers, fibrils, and paired helical filaments, and cell-to-cell spreading of these pathological tau species are critical processes underlying the pathogenesis of Alzheimer's disease and other tauopathies.
|
31046227 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Brain lesions in Alzheimer's disease (AD) include amyloid plaques made of Aβ peptides and neurofibrillary tangles composed of hyperphosphorylated tau protein with synaptic and neuronal loss and neuroinflammation.
|
30821420 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therapeutic strategies focusing on the reduction of oxidative stress, modulation of amyloid-beta (Aβ) toxicity and inhibition of tau protein hyperphosphorylation are warranted to avoid the development and progression of AD.
|
30763379 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we give a brief description of the pathogenesis of AD and provide detailed discussions about the recent development of chemical structures of anti-AD agents (2013 up to present) that have multiple targets, such as amyloid-β peptide, Tau protein, cholinesterases, monoamine oxidase, β-site amyloid-precursor protein-cleaving enzyme 1, free radicals, metal ions (Fe2+, Cu2+, Zn2+) and so on.
|
30501591 |
2019 |
|
Alzheimer's Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we found that streptozotocin (STZ)-induced diabetic rats exhibited poorer performance on the social recognition test, Morris water maze, and plus-maze discriminative avoidance task, compared to PBS-treated normoglycemic control rats, likely resulting from increased brain deposition of amyloid-β peptide aggregates (Aβ) and increased phosphorylation of tau protein, two pathological features of AD.
|
30958383 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared to older Caucasians, older African Americans have higher risks of developing Alzheimer disease (AD) and lower cerebrospinal fluid (CSF) tau biomarker levels.
|
31271450 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The intrinsically disordered tau protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and other human tauopathies.
|
31470053 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) and other tauopathies are characterized by intracellular accumulation of microtubule-associated tau protein leading to neurodegeneration.
|
31156179 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The formation of senile plaques and neurofibrillary tangles of the tau protein are the main pathological mechanism of Alzheimer's disease (AD).
|
29338678 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Aggregates of hyperphosphorylated tau protein are a hallmark of Alzheimer's disease (AD) and other tauopathies.
|
31702011 |
2019 |